


CANCER THERAPY

PRESCRIBING AND
ADMINISTRATION BASICS



Edited by

TRINH PHAM, PHARM D, BCOP

Associate Clinical Professor

University of Connecticut School of Pharmacy

Storrs, Connecticut

LISA HOLLE, PHARM D, BCOP

Assistant Clinical Professor

University of Connecticut School of Pharmacy

Storrs, Connecticut



JONES & BARTLETT
LEARNING

World Headquarters
Jones & Bartlett Learning
5 Wall Street
Burlington, MA 01803
978-443-5000
info@jblearning.com
www.jblearning.com

Jones & Bartlett Learning books and products are available through most bookstores and online booksellers. To contact Jones & Bartlett Learning directly, call 800-832-0034, fax 978-443-8000, or visit our website, www.jblearning.com.

Substantial discounts on bulk quantities of Jones & Bartlett Learning publications are available to corporations, professional associations, and other qualified organizations. For details and specific discount information, contact the special sales department at Jones & Bartlett Learning via the above contact information or send an email to specialsales@jblearning.com.

Copyright © 2015 by Jones & Bartlett Learning, LLC, an Ascend Learning Company

All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without written permission from the copyright owner.

The content, statements, views, and opinions herein are the sole expression of the respective authors and not that of Jones & Bartlett Learning, LLC. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not constitute or imply its endorsement or recommendation by Jones & Bartlett Learning, LLC and such reference shall not be used for advertising or product endorsement purposes. All trademarks displayed are the trademarks of the parties noted herein. *Cancer Therapy: Prescribing and Administration Basics* is an independent publication and has not been authorized, sponsored, or otherwise approved by the owners of the trademarks or service marks referenced in this product.

There may be images in this book that feature models; these models do not necessarily endorse, represent, or participate in the activities represented in the images. Any screenshots in this product are for educational and instructive purposes only. Any individuals and scenarios featured in the case studies throughout this product may be real or fictitious, but are used for instructional purposes only.

The authors, editor, and publisher have made every effort to provide accurate information. However, they are not responsible for errors, omissions, or for any outcomes related to the use of the contents of this book and take no responsibility for the use of the products and procedures described. Treatments and side effects described in this book may not be applicable to all people; likewise, some people may require a dose or experience a side effect that is not described herein. Drugs and medical devices are discussed that may have limited availability controlled by the Food and Drug Administration (FDA) for use only in a research study or clinical trial. Research, clinical practice, and government regulations often change the accepted standard in this field. When consideration is being given to use of any drug in the clinical setting, the health care provider or reader is responsible for determining FDA status of the drug, reading the package insert, and reviewing prescribing information for the most up-to-date recommendations on dose, precautions, and contraindications, and determining the appropriate usage for the product. This is especially important in the case of drugs that are new or seldom used.

Production Credits

Executive Publisher: William Brottmiller
Executive Editor: Rhonda Dearborn
Associate Editor: Teresa Reilly
Editorial Assistant: Sean Fabery
Production Editor: Cindie Bryan
Marketing Manager: Grace Richards
VP, Manufacturing and Inventory Control:
Therese Connell

Composition: Laserwords Private Limited, Chennai,
India

Cover Design: Kristin E. Parker

Photo Research and Permissions Coordinator:
Amy Rathburn

Cover and Title Page Images: Background: © _Lonely_/Shutterstock, Inc., Left: © Li Wa/Shutterstock, Inc., Middle: © Wavebreakmedia Ltd/Shutterstock, Inc., Right: © jordache/Shutterstock, Inc.

Printing and Binding: Edwards Brothers Malloy
Cover Printing: Edwards Brothers Malloy

Library of Congress Cataloging-in-Publication Data

Pham, Trinh, author.

Cancer therapy : prescribing and administration basics / Trinh Pham, Lisa Holle.
p. : cm.

Includes bibliographical references and index.

ISBN 978-1-4496-3397-4 (pbk.) – ISBN 1-4496-3397-8 (pbk.)

I. Holle, Lisa, author. II. Title.

[DNLM: 1. Neoplasms—drug therapy. 2. Antineoplastic Agents—administration & dosage. 3. Antineoplastic Agents—therapeutic use. QZ 267]

RC271.C5

616.99'4061—dc23

6048

2013028713

Printed in the United States of America

17 16 15 14 13 10 9 8 7 6 5 4 3 2 1

Dedication

This book is dedicated to all of our patients who have undergone the journey of cancer and from whom we've learned so much about cancer therapy and so much more.

Contents

Preface xiii

About the Editors xv

Contributors xvii

Reviewers xxi

CHAPTER 1

Overview of Cancer Therapy 1

Lisa Holle, Jane Pruemer, Hyejin Kim

Introduction 1

What Is Cancer? 1

Modalities of Cancer Treatment 4

Cancer Therapy Medications 5

Classes of Chemotherapy Agents 5

Microtubule-Targeting Drugs 5

Vinca Alkaloids 6

Taxanes 6

Epothilones 7

Eribulin 14

Estramustine 15

Alkylating Agents 15

Nitrogen Mustard and Its Derivatives 15

Nitrosoureas 16

Nonclassical Alkylating Agents 16

Heavy Metal Compounds 17

Antimetabolites 17

Pyrimidines 18

Cytidine Analogs 18

Purine Antimetabolites 19

Antifolates 19

<i>Topoisomerase Inhibitors</i>	20
Camptothecin Derivatives	20
Podophyllotoxin Derivatives	21
Anthracene Derivatives	21
<i>Miscellaneous Agents</i>	22
Targeted Therapy	24
<i>Monoclonal Antibodies</i>	24
<i>Angiogenesis Inhibitors</i>	26
<i>Immunomodulators</i>	26
<i>Tyrosine Kinase Inhibitors</i>	26
<i>Miscellaneous Targeted Agents</i>	29
<i>Interferon and Interleukin-2</i>	30
Hormonal Agents	30
<i>Antiestrogens</i>	30
<i>Aromatase Inhibitors</i>	30
<i>Luteinizing Hormone Releasing Hormone Analogs and Antagonists</i>	31
<i>Antiandrogens</i>	31
Response to Treatment	32
<i>Performance Status</i>	32
Summary	35
References	35
Suggested Reading	38

CHAPTER 2

Basics of Systemic Anticancer Therapy Prescribing and Verification 39

Trinh Pham, Joan Rivington

Introduction	40
Oncology Training	40
Education	43
Cancer Therapy Prescribing	44
<i>Computerized Provider-Order-Entry for Anticancer Agents</i>	45
<i>Strategies to Prevent Errors in Cancer Therapy Prescribing</i>	46
<i>The Prescribing Vocabulary—Anticancer Therapy Regimen Cycle</i>	51
<i>Dose Calculation</i>	52
<i>References</i>	54
<i>Investigational Anticancer Regimens or Medications</i>	54
Cancer Therapy Verification	55

Oral Anticancer Therapy	58
Intrathecal Anticancer Therapy	60
<i>Anticancer Agents for Intrathecal Administration and Dosing Considerations</i>	60
<i>Avoid Intrathecal Vincristine Injection</i>	61
Supportive Care and Ancillary Medications	62
<i>Infusion-Related Reactions</i>	63
<i>Tumor Lysis Syndrome</i>	64
<i>Chemotherapy-Induced Nausea and Vomiting</i>	64
<i>Febrile Neutropenia and Colony-Stimulating Growth Factors</i>	68
Nononcology Indications for Anticancer Therapy	68
Resources	69
Summary	69
References	70
Suggested Reading	71

CHAPTER 3

Dosing Calculations 73

Trinh Pham, Man Yee Merl, Jia Li

Introduction	73
Methods for Dose Calculation	74
BSA-Based Dosing	75
<i>Dose Calculation in Obese and Underweight Patients</i>	78
<i>Dose Calculation in Adult Amputees</i>	81
Pharmacokinetic-Based Dosing—Area Under the Curve	82
<i>Carboplatin Dosing</i>	82
Flat Fixed-Dose Dosing System	85
Genotype-Guided Dosing	85
Dose Rounding	88
Organ Function Assessment and Anticancer Therapy Dosing	88
<i>Renal Function Assessment and Anticancer Therapy Dosing</i>	89
<i>Dose and Administration Modification in Hemodialysis Setting</i>	102
<i>Hepatic Function Assessment and Anticancer Therapy Dosing</i>	105
Summary	106
References	107
Suggested Websites and Readings	110

CHAPTER 4**Cancer Therapy Preparation 111***Michele Rice, Jeanne Adams, James G. Stevenson*

Introduction 112

Cancer Therapy Preparation Area: The Cleanroom 113

Environmental Controls 113

Cancer Therapy Production: Cleanroom

Processes 120

Personal Protective Equipment 120*Cleaning Regimens* 123

Chemotherapy Spills 124

Storage and Dispensing 124*Refrigeration* 128*Safe Disposal of Hazardous Drug Waste* 131

Cancer Therapy Preparation Personnel: The

Multidisciplinary Team 133

The Pharmacist 134*The Nurse* 135*The Pharmacy Technician* 136*Ideal Staffing* 137

Summary 137

References 137

CHAPTER 5**Oral Cancer Therapy 139***Beth Chen, Lisa Holle*

Introduction 139

Dosing and Administration 141

Side Effects 145

Skin Toxicity 147*Cardiovascular Toxicity* 148*Gastrointestinal Toxicity* 149*Fatigue* 150*Toxicities of Hormonal Agents* 151

Drug and Food Interactions 152

Counseling and Monitoring 156

Adherence 158

Safe Prescribing and Dispensing Practices 160

*Risk Evaluation Mitigation Strategy (REMS)**Requirements* 162

Safe Handling 164

Financial Considerations 165

Summary 168

References 169

CHAPTER 6 Drug Safety and Risk Management 171*Karen R. Smethers*

Introduction 172

Types of Chemotherapy Errors in the Medication Use

Process 174

Procurement 174*Prescribing* 177*Transcribing/Documenting* 178*Compounding/Dispensing* 179*Administering* 183*Monitoring* 186

Preventing Chemotherapy Medication Errors 186

Ready Access to Pertinent Patient Information 186*Ready Access to Medication Information* 187*Standardized Chemotherapy Order Forms and Checking**Process* 188*Preventing Look-Alike and Sound-Alike Medication**Errors* 189*Preventing Wrong-Route Errors Associated With**Intrathecal Therapy* 192*Employ Technology* 193*Provide a Safe Work Environment* 193

Medication Error Reporting 194

Sentinel Event Reporting 194

Adverse Event Reporting 195

Risk Evaluation and Mitigation Strategies 196

Summary 198

References 199

CHAPTER 7 Inventory and Reimbursement 203*Timothy Tyler, Lisa Holle*

Introduction 203

Inventory 204

Accounting 204*Purchasing* 206*340B Pricing* 211

Reimbursement 213

Payers 213

Medicare 213

Medicaid 216

Private Insurance 217

<i>Coverage</i>	217
<i>Patient Assistance Programs</i>	220
Summary	220
References	221

CHAPTER 8**High-Dose Cancer Therapy 223**

Laura E. Wiggins, Ashley Richards

Overview of Hematopoietic Stem Cell Transplantation	223
<i>Types of HSCT</i>	224
<i>Collection of Hematopoietic Stem Cells</i>	229
<i>Infusion of HSCs</i>	231
Supportive Care and Transplant-Related Complications	233
<i>Chemotherapy-Induced Nausea and Vomiting</i>	233
<i>Cytopenias</i>	236
<i>Graft-Versus-Host Disease</i>	237
Prevention of Acute GVHD	239
Pharmacologic Prophylaxis of Acute GVHD	239
GVHD Treatment	245
<i>Steroid Refractory GVHD</i>	246
Supportive Care for Acute GVHD	247
Chronic GVHD	248
Treatment of Chronic GVHD	253
Sinusoidal Obstruction Syndrome	257
<i>Treatment of SOS</i>	258
<i>Infection in HSCT Patients</i>	259
Summary	262
References	262

CHAPTER 9**Pediatric Oncology 267**

Brooke Bernhardt, Susannah E. Koontz

Introduction	267
Role of Cooperative Research Groups	268
Initial Presentation and Oncologic Emergencies	269
<i>Initial Presentation</i>	269
<i>Oncologic Emergencies</i>	270
Hyperleukocytosis	270
Tumor Lysis Syndrome	270
Superior Vena Cava Syndrome	271

Acute Leukemias	271
<i>Acute Lymphoblastic Leukemia</i>	271
Down Syndrome and ALL	274
<i>Acute Myeloid Leukemia</i>	274
Down Syndrome and AML	275
<i>Acute Promyelocytic Leukemia</i>	276
Lymphomas	276
<i>Hodgkin's Lymphoma</i>	276
<i>Non-Hodgkin's Lymphoma</i>	277
Central Nervous System Tumors	278
Common Solid Tumors of Childhood	280
<i>Neuroblastoma</i>	280
<i>Wilms' Tumor</i>	281
<i>Rhabdomyosarcoma</i>	281
<i>Osteosarcoma</i>	282
<i>Ewing's Sarcoma</i>	282
<i>Retinoblastoma</i>	283
Supportive Care	284
Chemotherapy-Induced Nausea and Vomiting	284
Bone Marrow Support	285
Survivorship and Long-Term Toxicities	285
Special Dosing Considerations	286
Fluid Management	289
Chemotherapy Dosing in Infants	290
Obese Children	293
Outpatient Pediatric Oncology	295
<i>Medication Errors in the Outpatient Setting</i>	295
<i>Oral Chemotherapy Formulations</i>	298
<i>Outpatient Pediatric Oncology</i>	298
Summary	298
References	299

CHAPTER 10

Investigational Drugs 303

Theresa A. Mays, Leslie Smetzer

Introduction	303
Documentation	304
Standard Operating Procedures	305
Issues Affecting the Patient's Enrollment in the Clinical Trial	309

Common Terminology Criteria for Adverse Events	312
Clinical Trial Medication Issues	316
<i>Drug Accountability Records</i>	316
<i>Drug Preparation and Administration Issues</i>	319
<i>Dispensing Oral Agents</i>	320
<i>Bioequivalence and Bioavailability Studies</i>	320
<i>Hazardous Versus Biohazardous Drugs</i>	321
Code of Federal Regulations Title 21(1) and the International Conference on Harmonization Guideline for Good Clinical Practice	322
Summary	323
References	323

CHAPTER 11 **Pharmacogenetics and Pharmacogenomics in Cancer Therapy** 325

Trinh Pham, Man Yee Merl, Jia Li

Introduction	325
Terminology	326
Biomarkers That Predict Treatment Toxicity	327
<i>Thiopurine S-Methyltransferase</i>	327
<i>Dihydropyrimidine Dehydrogenase</i>	329
<i>Uridine Diphosphoglucuronosyltransferase 1A1</i>	329
Biomarkers That Predict Treatment Response and/or Prognosis	330
<i>Estrogen Receptor/Progesterone Receptor</i>	330
<i>Human Epidermal Growth Factor Receptor 2</i>	333
<i>Epidermal Growth Factor Receptor</i>	334
<i>K-RAS</i>	335
<i>EML4-ALK Fusion Gene</i>	337
<i>BRAF</i>	338
<i>BCR/ABL Chromosomal Translocation (Philadelphia Chromosome)</i>	339
<i>Promyelocytic Leukemia/Retinoic Acid Receptor- Alpha</i>	339
<i>Deletion of Chromosome 5q</i>	340
<i>O⁶-Methyl Guanine Methyl Transferase</i>	340
Summary	341
References	341
Suggested Reading	345

Index 347

Preface

As practicing oncology pharmacists, we are often asked about the practical, day-to-day aspects of cancer therapy prescribing, verification, admixing, administration, and cost/reimbursement. As teachers, we find that there is not one comprehensive reference source that addresses all of these issues in the available pharmacy, nursing, or medicine textbooks. For these reasons, we decided to publish *Cancer Therapy: Prescribing and Administration Basics* to fulfill this unmet need for practicing or in-training nurses, nurse practitioners, physician assistants, pharmacists, and hematology/oncology physician fellows who work with cancer patients. Healthcare professionals whose primary area of practice is not hematology/oncology but who may be responsible for verifying, preparing, dispensing, or administering cancer therapy agents will also find this textbook useful. The goal of this book is to optimize safe and effective care of cancer patients in a variety of healthcare settings, including hospitals, ambulatory care clinics, and private oncology practices.

The purpose is to provide a multidisciplinary, comprehensive, hands-on, practical guide of cancer therapy basics for oncology clinicians. Each chapter focuses on the various clinical and practice-related aspects of the delivery of cancer therapies, from prescribing through reimbursement, and chapters on special populations such as pediatrics and stem cell transplantation are included. The information is presented in a simple and direct way and includes the following:

- Checklists to ensure safe and consistent reviews of cancer therapy orders
- Common equations used in oncology
- Tables with key information for an easy-to-read and refer-to format
- Clinical pearls that are often learned on the job rather than in textbooks

- Comprehensive patient case examples with answers to emphasize key concepts and provide the reader an opportunity to apply the knowledge
- Listings of additional practical resources and recommended readings to enhance depth of knowledge for those who desire it

We thank each contributing author for offering his or her expertise and insightful clinical pearls to make this textbook complete. Your contributions are truly appreciated. We are also grateful to the peer reviewers for offering their time and outstanding critiques of each of the chapters. Finally, we thank our colleagues and mentors for their support and inspiration, our students and trainees for continually challenging us, and our patients for reminding us why we do what we do.

Trinh and Lisa

About the Editors

Trinh Pham, PharmD, BCOP, is an Associate Clinical Professor at the University of Connecticut's School of Pharmacy. Her practice site is at the Smilow Cancer Center at the Yale-New Haven Hospital, where she provides education to the oncology pharmacists, pharmacy residents, and pharmacy students along with the medical oncology team in the areas of pain management and supportive care. Dr. Pham completed her bachelor of science in pharmacy degree at the University of Texas in Austin. She also completed a post-baccalaureate doctor of pharmacy degree and a specialized oncology residency and fellowship at the University of Oklahoma. Dr. Pham is a board-certified oncology pharmacist. Her clinical and research interests include pain management and supportive care. Dr. Pham is a member of the Hematology/Oncology Pharmacy Association and the American Society of Clinical Oncology.

Lisa Holle, PharmD, BCOP, is an Assistant Clinical Professor at the University of Connecticut's School of Pharmacy. Her practice site is at the University of Connecticut Health Center's Carole and Ray Neag Comprehensive Cancer Center, where she works with the medical oncology team to provide management of oral cancer therapy, supportive care, and pain management. Dr. Holle completed her bachelor of science degree in pharmacy and a post-baccalaureate doctor of pharmacy degree from the University of Wisconsin at Madison. She completed a specialized oncology residency at The University of Texas M.D. Anderson Cancer Center and is a board-certified oncology pharmacist. Dr. Holle is a past president of the Hematology/Oncology Pharmacy Association and is a member

of many professional pharmacy and oncology organizations. Her clinical research program focuses on oncology quality improvement initiatives, drug shortages, oral cancer therapy management, and supportive care reimbursement for clinical pharmacy services.

Contributors

Jeanne Adams, CPhT

IV Prep Supervisor
Illinois CancerCare
Peoria, Illinois

Brooke Bernhardt, PharmD, MS, BCOP

Group Pharmacist, Children's Oncology Group
Clinical Pharmacy Specialist, Oncology
Texas Children's Hospital
Houston, Texas

Beth Chen, PharmD, BCOP

Oncology Clinical Specialist
Biologics, Inc
Cary, North Carolina

Hyejin Kim, PharmD

Pharmacist
Department of Pharmacy Services
The William W. Backus Hospital
Norwich, Connecticut

Susannah E. Koontz, PharmD, BCOP

Principal and Consultant—Pediatric Hematology/Oncology/HSCT
Koontz Oncology Consulting, LLC
Houston, Texas

Jia Li, MD, PhD

Assistant Professor
VA Connecticut Healthcare System
Yale Cancer Center
Yale School of Medicine
New Haven, Connecticut

Theresa A. Mays, BS, PharmD, BCOP, FASHP

Director, Investigational Drug Section
South Texas Accelerated Research Therapeutics
San Antonio, Texas

Man Yee Merl, BS, PharmD, BCOP

Senior Clinical Specialist, Oncology Pharmacy Services
Department of Oncology Pharmacy Services
Smilow Cancer Hospital at Yale–New Haven
New Haven, Connecticut

Jane Pruemer, PharmD, BS Pharm, BCOP, FASHP

Clinical Professor of Pharmacy Practice
Department of Pharmacy Practice and Administrative Sciences
University of Cincinnati James L. Winkle College of Pharmacy
Cincinnati, Ohio

Michele Rice, PharmD, BCOP

Director of Pharmacy and Research
Illinois CancerCare
Peoria, Illinois

Ashley Richards, PharmD, BCOP

Clinical Pharmacy Specialist, BMT/Leukemia
Department of Pharmacy
UF Health Shands Hospital
Clinical Assistant Professor
Department of Pharmacotherapy and Translational Research
University of Florida College of Pharmacy
Gainesville, Florida

Joan Rivington, MPharm, BCOP

Clinical Oncology Pharmacist
Lawrence and Memorial Cancer Center
Waterford, Connecticut

Karen R. Smethers, BS, PharmD, BCOP

National Clinical Pharmacy Integration Leader
Ascension Health
St. Louis, Missouri

Leslie Smetzer, BSN, RN, OCN

Director, Phase I Nursing
South Texas Accelerated Research Therapeutics (START)
San Antonio, Texas

James G. Stevenson, PharmD, FASHP

Chief Pharmacy Officer
University of Michigan Health System
Professor and Associate Dean for Clinical Sciences
University of Michigan College of Pharmacy
Ann Arbor, Michigan

Timothy Tyler, PharmD, FCSHP

Director of Pharmacy Services
Comprehensive Cancer Center
Desert Regional Medical Center
Associate Adjunct Professor
University of Southern California School of Pharmacy
Palm Springs, California

Laura E. Wiggins, PharmD, BCOP

Clinical Chief, Oncology Pharmacy Services
UF Health Shands Hospital
Clinical Assistant Professor
Department of Pharmacotherapy and Translational Research
University of Florida College of Pharmacy
Gainesville, Florida

Reviewers

Sandra Cuellar, PharmD, BCOP

Director, PGY-2 Oncology Pharmacy Residency
Clinical Assistant Professor
Department of Pharmacy Practice
University of Illinois Medical Center
Chicago, Illinois

Ryan A. Forrey, PharmD, MS

Associate Director, Pharmacy and Infusion Services
The Ohio State University Comprehensive Cancer Center: Arthur G. James
Cancer Hospital and Richard J. Solove Research Institute
Clinical Assistant Professor
College of Pharmacy
The Ohio State University
Columbus, Ohio

Rebecca E. Greene, PharmD, BCOP

Orlando VA Medical Center
Orlando, Florida

Suzanne Jones, PharmD

Scientific Director
Sarah Cannon Research Institute
Nashville, Tennessee

James J. Natale, PharmD, BCOP

Clinical Pharmacy Specialist

UPMC Cancer Center

Pittsburgh, Pennsylvania

Lisa A. Thompson, PharmD, BCOP

Assistant Professor

Department of Clinical Pharmacy

University of Colorado Skaggs School of Pharmacy and

Pharmaceutical Sciences

Aurora, Colorado

Scott Wirth, PharmD, BCOP

Clinical Assistant Professor

Department of Pharmacy Practice

Clinical Pharmacist, Oncology

University of Illinois at Chicago

Chicago, Illinois